LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Calyx focused on oral therapies for diabetes and inflammatory diseases, utilizing natural plant extracts with demonstrated clinical activity in humans as the source of its discovery efforts. Working with this company, Pappas Ventures expanded our expertise in oral therapies. Theracos acquired the company’s assets in 2003.
Calyx Therapeutics
Hayward, CA
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.